Literature DB >> 12542520

Fibroblast activation protein: differential expression and serine protease activity in reactive stromal fibroblasts of melanocytic skin tumors.

Margit A Huber1, Norbert Kraut, John E Park, Roland D Schubert, Wolfgang J Rettig, Ralf U Peter, Pilar Garin-Chesa.   

Abstract

Growth and metastasis of solid neoplasms require the recruitment of a supporting tumor stroma. A highly consistent trait of tumor stromal fibroblasts in most epithelial cancers is the induction of fibroblast activation protein (FAP), a member of the serine protease family. Recently it was demonstrated that FAP has both dipeptidyl peptidase and collagenolytic activity capable of degrading gelatin and type I collagen. In this study, we describe the expression and enzyme activity of FAP in benign and malignant melanocytic skin tumors. FAP-positive fibroblasts were detected immunohistochemically in the reactive stroma of all melanocytic nevi tested. In primary and metastatic melanomas an upregulation of FAP expression in the reactive mesenchyme could be observed. Whereas 30% of the nevi revealed additional FAP expression on subsets of melanocytic cells, melanoma cells from primary and metastatic melanomas were FAP negative. This may indicate a possible role for FAP in the control of tumor cell growth and proliferation during melanoma carcinogenesis. Consistent with this in vivo expression pattern FAP enzyme activity could be detected by a specific immunocapture assay in extracts of melanocytic nevi and melanoma metastases, whereas no significant activity was detectable in normal adult skin. Strong protein expression of FAP was observed in patterned structures restricted to a subset of the melanoma metastases. Our findings that these FAP-positive structures showed no overlap with endothelial cell surface markers, nor with various melanoma antigens, suggest that FAP is a marker for specific stromal-cell-derived patterns in cutaneous melanoma metastases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12542520     DOI: 10.1046/j.1523-1747.2003.12035.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  42 in total

Review 1.  Insidious changes in stromal matrix fuel cancer progression.

Authors:  Fayth L Miles; Robert A Sikes
Journal:  Mol Cancer Res       Date:  2014-01-22       Impact factor: 5.852

Review 2.  The role of fibroblast activation protein in health and malignancy.

Authors:  Allison A Fitzgerald; Louis M Weiner
Journal:  Cancer Metastasis Rev       Date:  2020-09       Impact factor: 9.264

Review 3.  Potential disease biomarkers: dipeptidyl peptidase 4 and fibroblast activation protein.

Authors:  Roger Yazbeck; Simone E Jaenisch; Catherine A Abbott
Journal:  Protoplasma       Date:  2017-06-16       Impact factor: 3.356

Review 4.  A visual-quantitative analysis of fibroblastic stromagenesis in breast cancer progression.

Authors:  Edna Cukierman
Journal:  J Mammary Gland Biol Neoplasia       Date:  2004-10       Impact factor: 2.673

5.  Immunotherapy of tumor with vaccine based on basic fibroblast growth factor-activated fibroblasts.

Authors:  Xiuying Li; Yongsheng Wang; Yuwei Zhao; Hengxiu Yang; Aiping Tong; Chengjian Zhao; Huashan Shi; Yang Li; Zhenlin Wang; Yuquan Wei
Journal:  J Cancer Res Clin Oncol       Date:  2013-12-10       Impact factor: 4.553

6.  Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity.

Authors:  Liang-Chuan S Wang; Albert Lo; John Scholler; Jing Sun; Rajrupa S Majumdar; Veena Kapoor; Michael Antzis; Cody E Cotner; Laura A Johnson; Amy C Durham; Charalambos C Solomides; Carl H June; Ellen Puré; Steven M Albelda
Journal:  Cancer Immunol Res       Date:  2013-11-12       Impact factor: 11.151

7.  Inhibitor of DASH proteases affects expression of adhesion molecules in osteoclasts and reduces myeloma growth and bone disease.

Authors:  Angela Pennisi; Xin Li; Wen Ling; Sharmin Khan; Dana Gaddy; Larry J Suva; Bart Barlogie; John D Shaughnessy; Nazneen Aziz; Shmuel Yaccoby
Journal:  Br J Haematol       Date:  2009-04-08       Impact factor: 6.998

8.  Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice.

Authors:  Angélica M Santos; Jason Jung; Nazneen Aziz; Joseph L Kissil; Ellen Puré
Journal:  J Clin Invest       Date:  2009-11-16       Impact factor: 14.808

9.  Fibroblast activation protein-α, a stromal cell surface protease, shapes key features of cancer associated fibroblasts through proteome and degradome alterations.

Authors:  M M Koczorowska; S Tholen; F Bucher; L Lutz; J N Kizhakkedathu; O De Wever; U F Wellner; M L Biniossek; A Stahl; S Lassmann; O Schilling
Journal:  Mol Oncol       Date:  2015-08-11       Impact factor: 6.603

10.  Transcriptional regulation of seprase in invasive melanoma cells by transforming growth factor-β signaling.

Authors:  Shaun Tulley; Wen-Tien Chen
Journal:  J Biol Chem       Date:  2014-04-13       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.